GlassScriptPhysician profile
James V Lynott
NPI 1649277658
$19,311.13
in general payments reported to CMS, 2019-2025
44 companies · $3,780 in 2025
The $3,780 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,048 · 2020: $1,593 · 2021: $2,375 · 2022: $2,881 · 2023: $3,312 · 2024: $3,322 · 2025: $3,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,970 · Education: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,969.83 |
| Education | $443.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $4,129.78 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Abbvie INC. | $2,975.07 | 2019-2025 | |
| Janssen Biotech, INC. | $1,919.27 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $1,207.61 | 2019-2025 | |
| Amgen INC. | $963.49 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $948.84 | 2019-2025 | |
| Lilly USA, LLC | $867.54 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Mayne Pharma Commercial LLC | $737.07 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $682.88 | 2021-2025 | Libtayo, Dupixent |
| Leo Pharma INC. | $661.71 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $630.75 | 2019-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $480.50 | 2023-2024 | Zoryve |
| Pfizer INC. | $391.58 | 2019-2025 | |
| Dermira, INC. | $275.56 | 2019-2021 | |
| Incyte Corporation | $236.89 | 2021-2025 | Opzelura |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lynott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.